NCI

Microbial species in the mouth could be playing a role in colorectal cancer development, according to new research from epidemiologists at VUMC. Read More

Austin Kirschner and colleagues are learning more about how the cancer drug enzalutamide combines with radiation therapy to treat difficult prostate tumors. Read More

Stephen Fesik and colleagues have uncovered more details about how a crucial component of RAS proteins, which trigger about a third of all tumors, work. This finding will help advance the discovery of new cancer therapies. Read More

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered. Read More

David Cortez and colleagues have discovered a new DNA repair mechanism. Read More

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer. Read More

Timothy Cover, john Loh and colleagues have identified how a certain type of mutation influences the risk of premalignant and malignant changes in the stomach. Read More

Ken Lau and Guoqiang Gu have identified a critical biomarker in determining how a pancreatic progenitor cell will develop. Read More

New research led by Rebecca Cook demonstrates that an antiviral receptor called RIG-I has potent immunogenic and therapeutic effects in breast cancer. Read More

A recent study led by Xiao-Ou Shu and colleagues found that green tea drinking was associated with increased risk of type 2 diabetes in Chinese adults, possibly due to the use of pesticides on tea plants--though the researchers call for further study of the exact mechanism. Read More

Qi Liu, PhD, Ken Lau, PhD, and colleagues have developed a new tool, sc-UniFrac, to quantify diverse cell types in single-cell studies. Read More

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have identified several of the conditions that arise and have determined that they usually appear early in treatment. Read More

Jeffrey Rathmell and colleagues show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also be useful as a treatment for inflammatory and autoimmune diseases. Read More

James Patton and colleagues have demonstrated how colon cancer cells transmit genetic data to other cells. Read More

Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA. Read More

A new study by Harvey Murff finds that diabetics who take metformin have lower rates of liver cancer than those who take other diabetes drugs. Read More

Stephen Deppen and colleagues have developed an updated map showing new areas of increased risk for a common lung infection. Read More

Researchers led by melanoma researcher Douglas Johnson have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies. Read More

Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis. Read More

A five-year National Cancer Institute grant will fund an interdisciplinary research center for the study of small cell lung cancer, a highly aggressive, incurable form of the disease. Read More